Identification of a selective glucocorticoid receptor ligand for the treatment of chronic inflammation in type 2 diabetes mellitus

Tan,Haifeng; Wang,Wei; Yin,Xiangang; Li,Yao; Yin,Rui

doi:10.3892/etm.2014.1860

Identification of a selective glucocorticoid receptor ligand for the treatment of chronic inflammation in type 2 diabetes mellitus

Authors:
- Haifeng Tan
- Wei Wang
- Xiangang Yin
- Yao Li
- Rui Yin
View Affiliations

Affiliations: Health Examination Cente, The Second People's Hospital of Jinan, Shandong 250001, P.R. China, Community Health Service, The Second People's Hospital of Jinan, Shandong 250001, P.R. China, The Cardiovascular Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Comprehensive Interventional Therapy, General Hospital of Jinan Military Area Command, Jinan, Shandong 250021, P.R. China, Department of Reproductive Medicine, Reproductive Hospital Affiliated to Shandong University, Jinan, Shangdong 250021, P.R. China
Published online on: July 23, 2014 https://doi.org/10.3892/etm.2014.1860
Pages: 1111-1114

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to identify a new selective glucocorticoid receptor (GR) ligand for the treatment of chronic inflammation in type 2 diabetes mellitus. The IN Cell Analyzer 1000 platform was employed to screen for compounds that may promote GR nuclear translocation. A mammalian two-hybrid system and transactivation assaywere used to analyze the selected GR ligands and evaluate their activities for GR transcription and the recruitment of co‑activators. A novel selective GR ligand, compound Q40, was identified that was able to promote GR nuclear translocation in a short period of time. It increased the ability of GR to recruit co‑activators in a concentration‑dependent manner, but had no positive effect on GR transcriptional activity. In conclusion, an increase in the expression levels of gluconeogeneic genes, induced by the transcriptional activation of GR, is the predisposing factor most commonly associated with the side‑effects of glucocorticoids. The results suggest that compound Q40 is a ligand of the GR and exerts an agonistic action on the recruitment of co‑activators without sugar dysmetabolism‑related side‑effects. Thus, compound Q40 has the potential to be used as an anti‑inflammatory adjuvant therapy with minimal side‑effects in patients with type 2 diabetes mellitus.

View Figures

View References

1	Mitrou P, Lambadiari V, Maratou E, et al: Skeletal muscle insulin resistance in morbid obesity: the role of interleukin-6 and leptin. Exp Clin Endocrinol Diabetes. 119:484–489. 2011. View Article : Google Scholar : PubMed/NCBI
2	Oakley RH and Cidlowski JA: The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 132:1033–1044. 2013. View Article : Google Scholar : PubMed/NCBI
3	Deroo BJ and Archer TK: Glucocorticoid receptor-mediated chromatin remodeling in vivo. Oncogene. 20:3039–3046. 2001. View Article : Google Scholar : PubMed/NCBI
4	Nelson G, Wilde GJ, Spiller DG, et al: NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci. 116:2495–2503. 2003. View Article : Google Scholar : PubMed/NCBI
5	Segard-Maurel I, Rajkowski K, Jibard N, Schweizer-Groyer G, Baulieu EE and Cadepond F: Glucocorticosteroid receptor dimerization investigated by analysis of receptor binding to glucocorticosteroid responsive elements using a monomer-dimer equilibrium model. Biochemistry. 35:1634–1642. 1996. View Article : Google Scholar
6	Adcock IM and Caramori G: Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol. 79:376–384. 2001. View Article : Google Scholar : PubMed/NCBI
7	Al-Hejjaj WK, Numan IT, Al-Sa’ad RZ and Hussain SA: Anti-inflammatory activity of telmisartan in rat models of experimentally-induced chronic inflammation: Comparative study with dexamethasone. Saudi Pharm J. 19:29–34. 2011. View Article : Google Scholar : PubMed/NCBI
8	Terzic N, Vujcic M, Ristic-Fira A, Krstic-Demonacos M, Milanovic D, Kanazir DT and Ruzdijic S: Effects of age and dexamethasone treatment on glucocorticoid response element and activating protein-1 binding activity in rat brain. J Gerontol A Biol Sci Med Sci. 58:297–303. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kumar RK, Herbert C, Thomas PS, et al: Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther. 307:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
10	Smoak KA and Cidlowski JA: Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 125:697–706. 2004. View Article : Google Scholar : PubMed/NCBI
11	Baschant U and Tuckermann J: The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 120:69–75. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bledsoe RK, Montana VG, Stanley TB, et al: Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110:93–105. 2002. View Article : Google Scholar : PubMed/NCBI
13	Nicolaides NC, Galata Z, Kino T, Chrousos GP and Charmandari E: The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 75:1–12. 2010. View Article : Google Scholar : PubMed/NCBI
14	Schoneveld OJ, Gaemers IC and Lamers WH: Mechanisms of glucocorticoid signalling. Biochim Biophys Acta. 1680:114–128. 2004. View Article : Google Scholar
15	Nissen RM and Yamamoto KR: The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14:2314–2329. 2000. View Article : Google Scholar : PubMed/NCBI
16	Schäcke H, Berger M, Rehwinkel H and Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 275:109–117. 2007.PubMed/NCBI
17	Rosen J and Miner JN: The search for safer glucocorticoid receptor ligands. Endocr Rev. 26:452–464. 2005. View Article : Google Scholar : PubMed/NCBI
18	Clark AR and Belvisi MG: Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 134:54–67. 2012. View Article : Google Scholar : PubMed/NCBI